Quang Pham Sells Shares of Cadrenal Therapeutics, Inc. $CVKD
Key Points
- Quang Pham sold 3,666 shares of Cadrenal Therapeutics, Inc. ($CVKD) worth $13,124.
- $CVKD last traded around $3.33.
Quang Pham, Chairman, CEO and Interim CFO at Cadrenal Therapeutics, Inc. ($CVKD), sold 3,666 shares at an average price of $3.58, for a total transaction of $13,124. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Cadrenal Therapeutics, Inc. ($CVKD) Stock
Cadrenal Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.